Erratum to: Thiopurine S-methyltransferase testing in idiopathic pulmonary fibrosis: A pharmacogenetic cost-effectiveness analysis (Lung (2010) 188 (125-132) DOI: 10.1007/s00408-009-9217-8);Thiopurine S-methyltranferase testing in idiopathic pulmonary fibrosis: A pharmacogenetic cost-effectiveness analysis

Lung

Volumn 188, Issue 2, 2010, Pages 125-132

  Hagaman, Jared T ^a   Kinder, Brent W ^a   Eckman, Mark H ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Azathioprine; Decision support techniques; Idiopathic pulmonary fibrosis; Pharmacogenetics

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID DERIVATIVE; PREDNISONE; THIOPURINE METHYLTRANSFERASE; VITAMIN D;

ALLELE; ARTICLE; CLINICAL TRIAL; COMPUTER SIMULATION; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; GENOTYPE; HUMAN; INCIDENCE; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 77949874647     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-011-9290-7     Document Type: Erratum

References (48)

1. American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646-664
2. Walter N, Collard HR, King TE Jr (2006) Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3:330-338
3. Bouros D, Antoniou KM (2005) Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 26:693-702
4. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idio-pathic Interstitial Pneumonias (2002) Am J Respir Crit Care Med 165:277-304
5. Raghu G, Brown KK, Bradford WZ et al (2004) A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350:125-133
6. Demedts M, Behr J, Buhl R et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229-2242
7. Nicholson AG, Colby TV, Dubois RM et al (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213-2217
8. Raghu G, Depaso WJ, Cain K et al (1991) Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144:291-296
9. Launay D, Remy-Jardin M, Michon-Pasturel U et al (2006) High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 33:1789-1801
10. Wu A, Fuhlbrigge A (2008) Economic evaluation of pharmaco-genetic tests. Clin Pharmacol Ther 84:272-274
11. Singh A (2007) Pharmacogenomics\the potential of genetically guided prescribing. Aust Fam Physician 36:820-824
12. Mallal S, Phillips E, Carosi G et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568-579
13. SandersonS, EmeryJ,Higgins J(2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97-104
14. Schalekamp T, Brasse BP, Roijers JF et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects over-anticoagulation. Clin Pharmacol Ther 80:13-22
15. Eichelbaum M, Fromm MF, Schwab M (2004) Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26:180-185
16. Ingelman-Sundberg M (2008) Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 358:637-639
17. Perri D, Cole DE, Friedman O et al (2007) Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J 30:1014-1017
18. Flowers JR, Clunie G, Burke M et al (1992) Bronchiolitis oblit-erans organizing pneumonia: the clinical and radiological features of seven cases and a review of the literature. Clin Radiol 45:371-377
19. Ansari A, Hassan C, Duley J et al (2002) Thiopurine methyl-transferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 16:1743-1750
20. Schwab M, Schaffeler E, Marx C et al (2002) Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12:429-436
21. Gisbert JP, Gomollon F, Cara C et al (2007) Thiopurine meth-yltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 52:1262-1269
22. Kroplin T, Weyer N, Gutsche S et al (1998) Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 54:265-271
23. Kroplin T, Weyer N, Iven H (1998) Determination of thiopurine methyltransferase activity in erythrocytes using 6-thioguanine as the substrate. Adv Exp Med Biol 431:741-745
24. Meggitt SJ, Reynolds NJ (2001) Azathioprine for atopic dermatitis. Clin Exp Dermatol 26:369-375
25. Winter J, Walker A, Shapiro D et al (2004) Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20:593-599
26. Oh KT, Anis AH, Bae SC (2004) Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by poly-merase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 43:156-163
27. Fargher EA, Eddy C, Newman W et al (2007) Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8:1511-1519
28. McLeod HL, Siva C (2002) The thiopurine S-methyltransferase gene locus\implications for clinical pharmacogenomics. Phar-macogenomics 3:89-98
29. Yates CR, Krynetski EY, Loennechen T et al (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614
30. Gearry RB, Barclay ML, Burt MJ et al (2003) Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18:395-400
31. Ameyaw MM, Collie-Duguid ES, Powrie RH et al (1999) Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 8:367-370
32. Jang IJ, Shin SG, Lee KH et al (1996) Erythrocyte thiopurine methyltransferase activity in a Korean population. Br J Clin Pharmacol 42:638-641
33. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharma-cogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662
34. Collie-Duguid ES, Pritchard SC, Powrie RH et al (1999) The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9:37-42
35. Hindorf U, Lyrenas E, Nilsson A et al (2004) Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 39:1105-1112
36. Schaeffeler E, Fischer C, Brockmeier D et al (2004) Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14:407-417
37. Yan L, Zhang S, Eiff B et al (2000) Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 68:210-219
38. King TE Jr, Safrin S, Starko KM et al (2005) Analyses of efficacy end points in a controlled trial of interferon-{gamma}1b for idiopathic pulmonary fibrosis. Chest 127:171-177
39. Winterbauer RH, Hammar SP, Hallman KO et al (1978) Diffuse interstitial pneumonitis clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 65:661-672
40. Present DH, Meltzer SJ, Krumholz MP et al (1989) 6-Mercap-topurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 111:641-649
41. www.drugstore.com. Accessed 10 Sept 2008
42. Collard HR, Loyd JE, King TE Jr et al (2007) Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med 101:2011-2016
43. Eldar-Lissai A, Cosler LE, Culakova E et al (2008) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11:172-179
44. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutrope-nia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184
45. Talcott JA (2000) Outpatient management of febrile neutropenia. Int J Antimicrob Agents 16:169-171
46. Tomioka H, Imanaka K, Hashimoto K et al (2007) Health-related quality of life in patients with idiopathic pulmonary fibrosis\ cross-sectional and longitudinal study. Intern Med 46:1533-1542
47. Martinez F, Bradford W, Safrin S et al (2003) Rates and characteristics of death in patients with idiopathic pulmonary fibrosis (IPF). Chest 124:117S
48. Flaherty KR, Mumford JA, Murray S et al (2003) Prognostic implications of physiologic and radiographic changes in idio-pathic interstitial pneumonia. Am J Respir Crit Care Med 168:543-548